Glucagon-Like Peptide 1 (GLP-1) receptor agonists and Dipeptidyl Peptidase 4 (DPP-4) inhibitors, commonly employed in diabetes management, have been shown to reduce cardiovascular risk in patients, thereby potentially mitigating the deleterious effects of COPD [27,28]. This evidence concerns the gene GLP1R and chronic obstructive pulmonary disease.